Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Forest licenses US rights to Merz's memantine

Executive Summary

Forest Labs has licensed exclusive US rights to Merz GMBH & Co.'s Phase III NMDA receptor antagonist memantine for Alzheimer's disease, neuropathic pain, and AIDs-related dementia.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register